Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-302 (Prolifagen Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Prolifagen Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intramyocardial
01
Overview
PRO-302 is a preclinical-stage regenerative therapy developed by Prolifagen Therapeutics for the treatment of myocardial infarction and heart failure. The therapeutic consists of a microRNA-302 (miR-302) mimic encapsulated within a specialized hyaluronic acid-based hydrogel. This formulation is designed for sustained release over a period of 7 to 10 days following intramyocardial injection. The mechanism of action involves the delivery of miR-302 to damaged cardiomyocytes, where it inhibits the Hippo signaling pathway. By suppressing Hippo pathway activity, PRO-302 stimulates the proliferation of existing cardiomyocytes, promoting the regeneration of functional heart muscle and improving cardiac function after injury.
- Other names
- miR-302 hydrogelmiR302 hydrogelmiR 302 hydrogelProlifagen miR-302
02
Targets
BMI1 (Polycomb complex protein BMI-1)CDK2 (Cyclin-dependent kinase 2)CCND1 (Cyclin D1)Cyclin D2 (CCND2) mRNALATS2 (Large tumor suppressor kinase 2)RHOC (Ras homolog family member C)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on PRO-302 (Prolifagen Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-302 (Prolifagen Therapeutics).